Amgen Announces Top-Line Results of Trial to Reduce Cardiovascular Events With Aranesp(R) Therapy (TREAT) in CKD Patients With Type-... ( THOUSAND OAKS Calif...)

Navigation Links

Biology News Medicine News Biology Products Medicine Products Biology Definition Medicine Definition Biology Technology Medicine Technology Biology Dictionary Medicine Dictionary

HOME >> MEDICINE >> TECHNOLOGY

Amgen Announces Top-Line Results of Trial to Reduce Cardiovascular Events With Aranesp(R) Therapy (TREAT) in CKD Patients With Type-2 Diabetes

Date:8/25/2009

THOUSAND OAKS, Calif., Aug. 25 /PRNewswire-FirstCall/ -- Amgen (Nasdaq: AMGN) today announced that in a large, randomized, double-blind, placebo-controlled, Phase 3 study of patients with chronic kidney disease (CKD) (not requiring dialysis), anemia and type-2 diabetes (the Trial to Reduce Cardiovascular Endpoints with Aranesp((R)) Therapy, or TREAT), treatment of anemia with Aranesp((R) )(darbepoetin alfa) to a hemoglobin target of 13 g/dL had no statistically significant effect on either of two primary endpoints compared with placebo treatment. The two primary endpoints were a composite of time to all-cause mortality or cardiovascular morbidity (including heart failure, heart attack, stroke, or hospitalization for myocardial ischemia) and a composite of time to all-cause mortality or chronic renal replacement therapy. Among the elements that formed these composite endpoints, an excess of stroke events (a labeled risk of Aranesp therapy) occurred in the Aranesp-treated patients compared to those receiving placebo.

These summary results will be followed by full efficacy and safety analyses, which will be shared with global regulatory authorities and presented at an upcoming medical meeting later this year.

"TREAT was designed to answer important questions about the effects of erythropoiesis-stimulating agents (ESAs) on cardiovascular and renal outcomes in patients with renal insufficiency and type-2 diabetes. It is by any measure the most comprehensive analysis that has ever been performed to examine the impact of anemia therapy in patients who do not yet require dialysis. The trial will provide nephrologists with important information as they endeavor to improve renal care," said Roger M. Perlmutter, M.D., Ph.D., executive vice p
'/>"/>

SOURCE Amgen
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8
Related medicine technology :

1. Amgen Issues Statement on Outcomes of Advisory Committee for Reproductive Health Drugs (ACRHD) Meeting
2. Amgen Announces Positive Top-Line Results for Denosumab in Trial for Delay of Skeletal Related Events in Bone Metastases Patients Compared to Zometa(R)
3. CDC Foundation Partners with Amgen, CDC to Reduce Infections Among Cancer Patients
4. Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer
5. AMT Obtains License to Amgens GDNF Gene to Develop Treatment for Parkinsons Disease with AMTs Proprietary Gene Therapy Platform
6. Medarex to Receive Milestone Payment from Amgen
7. Arthritis Foundation Announces Amgen and Wyeth to Be Presenting Sponsor of the 2008 Arthritis Walk (R)
8. ISTA Pharmaceuticals Announces Positive Preliminary Phase 3 Clinical Results to Support sNDA Filing for Once-Daily Xibrom(TM) 0.09%
9. IDEV(R) Technologies Announces First Patient Enrolled in Multi-Center Clinical Trial of SUPERA(R) PERipheral Stent
10. Phytomedics Inc. Announces Publication of the Phase 2b Clinical Trial Results of an Extract of the Chinese Herbal Remedy Tripterygium wilfordii Hook F in Rheumatoid Arthritis
11. Bionovo Announces Second Quarter 2009 Highlights and Financial Results

Post Your Comments:

(Date:5/22/2013)... May 22, 2013 /PRNewswire-iReach/ -- MarketReportsOnline.com announces addition ... Guidebook Series (4) 2013 Edition Material and Clinical ... Drug Registration: A Guidebook of Registration Application for ... to its online database. The traditional ... are always regarded by occidental as mysterious medicines. ...

(Date:5/22/2013)... VANCOUVER, British Columbia , May 22, 2013 OncoGenex ... the development of novel therapeutics to target mechanisms of treatment ... investigational compounds, custirsen and OGX-427, will be presented as "Trials ... of the American Society of Clinical Oncology (ASCO) in ... 4. Despite the availability of drugs that ...

(Date:5/21/2013)... 2013 Concord Medical Services Holdings Limited ("Concord ... a leading specialty hospital management solution provider and operator ... centers in China and the parent of Chang,an Hospital, ... first quarter ended March 31, 2013 [1] . ... revenue, which consists of net revenues generated from the ...

[0] China Pharmaceutical Market Guidebook Series (4) 2013 Report [0] OncoGenex Announces Multiple 'Trials in Progress' Presentations at the 2013 ASCO Annual Meeting [0] Concord Medical Reports First Quarter 2013 Financial Results

... 28, 2011 Pharmasset, Inc. (Nasdaq: VRUS ) ... Conference being held May 2 to 4, 2011 at the ... Merrill Lynch Healthcare Conference being held May 10 to 12, ... Price, Pharmasset,s President and Chief Executive Officer, will provide an ...

... 28, 2011 The U.S. Food and Drug ... with prednisone (a steroid) to treat patients with ... prior docetaxel (chemotherapy). (Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO ... sex hormone testosterone stimulates prostate tumors to grow. ...

Cached Medicine Technology:Pharmasset to Present at Two Upcoming Investor Conferences 2 Pharmasset to Present at Two Upcoming Investor Conferences 3 FDA Approves Zytiga for Late-Stage Prostate Cancer 2 FDA Approves Zytiga for Late-Stage Prostate Cancer 3

Pharmasset to Present at Two Upcoming Investor Conferences FDA Approves Zytiga for Late-Stage Prostate Cancer

(Date:5/22/2013)... of the antidepressant Lexapro appears to help prevent ... study finds. The condition is known ... people with this condition may not develop noticeable ... blood supply, according to researchers from Duke University ... the researchers found that people taking the antidepressant ...

(Date:5/22/2013)... By Dennis Thompson HealthDay Reporter , , TUESDAY, ... Americans isn,t improving much, with about six in 10 ... in unhealthy behaviors like smoking, heavy drinking or not ... Tuesday by the U.S. Centers for Disease Control and ... of the lifestyle choices that have led to soaring ...

(Date:5/22/2013)... May 22 (HealthDay News) -- Roughly four in 10 ... pulmonary disease (COPD) actually do not have the lung ... Faulty diagnoses were made based on an evaluation of ... standard" disease test known as spirometry, which shows how ... amount of air they can exhale and how long ...

(Date:5/22/2013)... Atlanta, GA (PRWEB) May 22, 2013 ... marketing agency, JD Media Surge, LLC, E-Dentists.com has ... subjects. The blog will feature numerous topics of ... on treatment options and dental health. , ... element of dental Internet marketing. In addition to ...

(Date:5/22/2013)... Macedon, NY (PRWEB) May 22, 2013 ... other lean manufacturing improvements use the new Do-Done StepTracker ... coordination. “We use the Do-Done board to display the ... Each of our production cells and departments is listed ... top. As we start a project, the squares are ...

Breaking Medicine News(10 mins):Health News:Antidepressants May Be Helpful for Some Heart Patients: Study 2 Health News:Antidepressants May Be Helpful for Some Heart Patients: Study 3 Health News:Americans Still Making Unhealthy Choices: CDC 2 Health News:Americans Still Making Unhealthy Choices: CDC 3 Health News:COPD May Be Over-Diagnosed Among Uninsured 2 Health News:Dental SEO Blog Launched by E-Dentists.com in Partnership with JD Media Surge, LLC 2 Health News:Project Managers Organize Manufacturing Projects and Training with the New Steptracker Project Status Magnetic Whiteboards 2

[0] Antidepressants May Be Helpful for Some Heart Patients: Study [0] Americans Still Making Unhealthy Choices: CDC [0] COPD May Be Over-Diagnosed Among Uninsured [0] Dental SEO Blog Launched by E-Dentists.com in Partnership with JD Media Surge, LLC [0] Project Managers Organize Manufacturing Projects and Training with the New Steptracker Project Status Magnetic Whiteboards

... N.J., July 9 Red wine (resveratrol) pills appear to be ... to lead the way for patients and consumers to learn more ... do so. , , (Photo: http://www.newscom.com/cgi-bin/prnh/20090709/LA44390 ) , ... of red wine pills, a local cardiology group says it will ...

... Today Americans United for Life (AUL) President & CEO Dr. ... members, urging them to ask Judge Sotomayor the "Top Ten" most ... the Court as the Senators prepare for her confirmation hearings to ... CEO Dr. Charmaine Yoest said, "It,s important for the American people ...

... As part of its Patient Voices series, ... is featuring the stories of people from across the country who ... Patient Voices seeks to give a glimpse into the life ... diverse as the disease itself, and include actress/model and Lupus Foundation ...

... 1 diabetes or having a preceding infection are associated with more ... 49 years old, according to a Finnish study. Furthermore, heart failure ... cancer malignancy with 16 times the risk of death in stroke ... group, said Jukka Putaala, M.D., who led the study. Risk of ...

... The President of the American Chemical Society, ... President Obama,s nomination of Francis Collins, M.D., Ph.D., to ... other time in recent memory has there been such a ... of science to deliver solutions to the grand challenges facing ...

... hits $42 million a year , THURSDAY, July 9 (HealthDay News) ... at least $42 million a year, a new study finds. , ... 100,000 young people annually, said Dr. Warren Lo, lead author of ... but there is growing concern about the cost of medical care ...

Cached Medicine News:Health News:Local Heart Doctors First in Nation to Announce Active Investigation of Red Wine (Resveratrol) Pills, Issue Consumer Precautions 2 Health News:Local Heart Doctors First in Nation to Announce Active Investigation of Red Wine (Resveratrol) Pills, Issue Consumer Precautions 3 Health News:Local Heart Doctors First in Nation to Announce Active Investigation of Red Wine (Resveratrol) Pills, Issue Consumer Precautions 4 Health News:AUL President to Senate Judiciary Committee: Ask Top 10 Questions to Judge Sotomayor 2 Health News:The New York Times Website Patient Voices Series Features People Affected by Lupus 2 Health News:Stroke in Children Rare But Costly 2 Health News:Stroke in Children Rare But Costly 3

Local Heart Doctors First in Nation to Announce Active Investigation of Red Wine (Resveratrol) Pills, Issue Consumer Precautions AUL President to Senate Judiciary Committee: Ask Top 10 Questions to Judge Sotomayor The New York Times Website Patient Voices Series Features People Affected by Lupus Finnish study identifies factors that increase death in stroke patients ages 15 to 49 American Chemical Society praises nomination of Collins as NIH Director Stroke in Children Rare But Costly

... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...

... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...

Medicine Products:

Netromycin, Random Level Netilmicin, Random Level Neopterin Level Neonatal 5 Drug Panel, Meconium